我们的做法:应用MRI透明细胞可能性评分管理不确定肾肿块
横断面影像普及使偶然发现的不确定肾肿块持续增多,其中小肾肿块(≤4 cm)常见于老年合并症患者,约五分之一组织学为良性。本文综述基于多参数MRI的透明细胞可能性评分(ccLS),提供图像判读分步指南及临床实施建议,以无创识别最常见的透明细胞亚型。
要点
- ccLS基于多参数MRI无创识别肾肿块透明细胞亚型,该亚型是最常见且侵袭性最强的肾癌形式。
- 约五分之一小肾肿块组织学为良性,部分肾癌呈惰性行为,积极治疗未必降低肾癌特异性死亡率。
- 文中提供ccLS分步判读指南及临床实施附加指导,用于管理不确定肾肿块。
核心结论
- 基于多参数MRI的透明细胞可能性评分(ccLS)有助于无创识别透明细胞亚型,文中给出分步判读指南及临床实施指导。
研究设计与样本
- 综述,总结ccLS的判读方法并提供临床实施指导;原文未报告系统检索范围与纳入文献数量。
诊断标准与关键数值
- ccLS由多参数MRI得出,用于无创识别肾肿块透明细胞亚型;原文未报告具体评分阈值、敏感度、特异度或AUC数值。
临床应用与阅片要点
- 文中提供ccLS的逐步图像判读指南,并附临床实施附加指导。
- 原文指出,缺乏可靠的临床与影像侵袭性生物学预测标志物可加重患者焦虑并限制主动监测的临床应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The widespread use of cross-sectional imaging has led to a continuous increase in the number of incidentally detected indeterminate renal masses. Frequently, these clinical scenarios involve an older patient with comorbidities and a small renal mass (≤4 cm). Despite aggressive treatment in early stages of the disease, a clear positive effect in reducing kidney cancer-specific mortality is lacking, indicating that many renal cancers exhibit an indolent oncologic behavior. Furthermore, in general, one in five small renal masses is histologically benign and may not benefit from aggressive treatment. Although active surveillance is increasingly recognized as a management option for some patients, the absence of reliable clinical and imaging predictive biologic markers of aggressiveness can contribute to patient anxiety and limit its use in clinical practice. A standardized approach to the image interpretation of solid renal masses has not been broadly implemented. The clear cell likelihood score (ccLS) derived from multiparametric MRI is useful in noninvasively identifying the clear cell subtype, the most common and aggressive form of kidney cancer. Herein, a review of the ccLS is presented, including a step-by-step guide for image interpretation and additional guidance for its implementation in clinical practice.
引用
- Pedrosa, Cadeddu. How We Do It: Managing the Indeterminate Renal Mass with the MRI Clear Cell Likelihood Score. Radiology. 2021. PMID: 34904873. doi:10.1148/radiol.210034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。